The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Applications include detailed scientific rationale and supporting clinical evidence
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
This recognition demonstrate excellence in intellectual property (IP) value creation.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
